

This communication should be viewed by:

Primary Care Providers
Behavioral Health Providers
Clinical staff

Pharmaceutical Policies Updates Effective January 1, 2024

To view all current MVP Health Care® (MVP) Medical policies, *Sign In* at mvphealthcare.com and select *Resources*, then *Medical Policies*. All policies are reviewed at least once annually. This communication lists all impacted policies and their status. Policies fall into one of the following categories:

- **New** – Denotes a new policy
- **Updated** – Updated policies have content changes that may affect coverage criteria for services and/or drugs
- **Reviewed/No Changes** – Policies that have been reviewed but have no content change
- **Archived** – Denotes a policy that is no longer active

The following policies are effective December 1, 2023 and will be available for viewing on or before November 1, 2023. Hard copies of the policies are available upon request.

Pharmaceutical Policy Name	Status
Multiple Sclerosis Agents	Updated
GABA Receptor Modulators	Updated
Duchenne Muscular Dystrophy	Reviewed/No Changes
Duchenne Muscular Dystrophy Medicaid	Reviewed/No Changes
Movement Disorder	Updated
Botulinum Toxin Treatment	Reviewed/No Changes
Radicava	Reviewed/No Changes
Respiratory Syncytial Virus/Synagis (palivizumab)	Updated
Spravato	Reviewed/No Changes
Gabapentin ER	Reviewed/No Changes
Nuedexta	Reviewed/No Changes
Agents for female sexual dysfunction	Updated
Adalimumab	Updated
Monoclonal Antibodies for Alzheimer's Disease (formerly Aduhelm)	Updated
CAR-T Cell Therapy	Updated
Daybue	New
GLP-1 Receptor Agonist Retrospective	Archived
Select Oral Antipsychotics	Updated
MVP Medicare Part D Drug Management	Updated
Oral Allergen Immunotherapy Medications	Updated
Palforzia	Reviewed
Prostate Cancer	Reviewed/No Changes
Spinal Muscular Atrophy	Reviewed/No Changes
Zoladex-Medicaid	Reviewed/No Changes

To view all communications, visit mvphealthcare.com/FastFax

Questions? Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.



Herceptin (trastuzumab)- Medicaid	Reviewed/No Changes
Perjeta (pertuzumab)- Medicaid	Reviewed/No Changes
Avastin (bevacizumab)- Medicaid	Reviewed/No Changes
Cancer Guidance Program Oncology Medication Coverage and Review	New
Densoumab (Prolia and Xgeva)	New
Dose Rounding for Systemic therapy	New

It's Time to Recertify Your Patients!*

The Families First Coronavirus Response Act has expired. To learn how MVP can help your patients continue their coverage, visit mvphealthcare.com/recertification.

*Applies to Members enrolled in Medicaid, Child Health Plus (CHP), Health and Recovery Plan (HARP), and the Essential Plan (EP).

To view all faxed messages, visit mvphealthcare.com/FastFax.

Questions? Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.

